Akebia Therapeutics Inc (NASDAQ:AKBA)
| 2.27 Delayed Data As of 3:59pm ET |  -0.07 / -3.00%Today’s Change | 2.25 Today|||52-Week Range 13.71 | -64.16% Year-to-Date |
Latest AKBA News | Press Releases
| Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 12:35pm / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.34 |
| Today’s open | 2.35 |
| Day’s range | 2.26 - 2.37 |
| Volume | 392,353 |
| Average volume (3 months) | 5,597,081 |
| Market cap | $330.5M |
Data as of 3:59pm ET, 10/29/2020
Growth & Valuation
| Earnings growth (last year) | +4.52% |
| Earnings growth (this year) | +7.94% |
| Earnings growth (next 5 years) | +15.80% |
| Revenue growth (last year) | +61.26% |
| P/E ratio | NM |
| Price/Sales | 2.23 |
| Price/Book | 0.72 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XENEXenon Pharmaceutical... | +0.18 | +1.90% |
| CNCEConcert Pharmaceutic... | -0.28 | -2.50% |
| OVIDOvid Therapeutics In... | +0.09 | +1.84% |
| ACIUAC Immune SA | +0.06 | +1.28% |
Data as of 3:59pm ET, 10/29/2020
Financials
| Next reporting date | November 5, 2020 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $335.0M |
| Annual profit (last year) | -$279.7M |
| Net profit margin | -83.48% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
